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Background: Many treatment options for plantar fasciitis currently exist, some with
great success in pain relief. The objective of our study was to compare the use of
intralesional steroids with platelet-rich plasma (PRP), using pain scales and functional
evaluation, in patients with plantar fasciitis who did not respond to conservative
treatment.
Methods: A controlled, randomized, blinded clinical assay was performed. Patients were
assigned to one of the two groups by selecting a sealed envelope. The steroid treatment
group received 8 mg of dexamethasone plus 2 mL of lidocaine as a local anesthetic. The
PRP treatment group received 3 mL of PRP activated with 0.45 mL of 10% calcium
gluconate. All of the patients were evaluated at the beginning of the study, and at 2, 4, 8,
12, and 16 weeks post-treatment with the Visual Analog Scale (VAS), Foot and Ankle
Disability Index (FADI), and American Orthopedic Foot and Ankle Society (AOFAS)
scale.
Results: The right foot was the most frequently affected foot (63%). The average age of
the patients was 44.8 years (range, 24–61 years). All scales used (VAS, FADI and
AOFAS) showed that the difference was not statistically significant between the two
groups.
Conclusions: We can conclude that the use of PRP is an effective treatment method for
patients with plantar fasciitis who do not respond to conservative treatment because
PRP demonstrates an efficacy equal to that of steroids. However, the cost and the time
for preparation the PRP are two of the disadvantages of this treatment. (J Am Podiatr
Med Assoc 107(6): 490-496, 2017)
The pathology that is usually present in the medial
heel region has traditionally been known as plantar
fasciitis. However, recently, the term plantar
fasciosis has been used to dismiss the inflammatory
component and emphasize the degenerative nature
that is observed histologically in the insertion zone
in the calcaneus.1 Regardless of its inflammatory or
degenerative nature, this pathology is usually
described as heel pain in the medial calcaneal
tuberosity.2 It is estimated that 1 in 10 people may
experience heel pain at some point in their lives.3
Up to one third of cases may be bilateral4 and are
usually observed in patients of working age,
between 40 and 60 years old, patients with intense
physical activity, or in patients whose body mass
index is .30 kg/m2.4-7
The most common initial treatment includes the
use of analgesics, stretching exercises, and rest.
However, in cases where conservative treatment is
ineffective, infiltration with intralesional steroids is
often used. This procedure is usually effective in
patients with acute pain but produces only short-
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term pain relief.8 Customarily, these treatments are
accompanied by exercises for stretching the gas-
trocnemius and soleus muscles and the plantar
fascia itself.2,9 One of the most used treatment
methods is infiltration with steroids, which relieves
the pain rapidly, and reports have demonstrated its
effectiveness for treating plantar fasciitis.2 Howev-
er, complications have also been described with its
use, such as application site infections, heel fat pad
atrophy, and plantar fascia rupture. Although the
rupture of the fascia may help to resolve the pain, it
usually affects the biomechanics of the foot.10,11
Recently, platelet-rich plasma (PRP) has been
used as a therapeutic alternative for obtaining relief
and resolution of symptoms. There are various
modalities of PRP preparation, which result in
greater or lesser concentrations of leukocytes
according to the number of centrifugations used
and the revolution velocity employed. There are
currently several trademarked products on the
market that can be used. The biotechnology now
in use has reportedly been successfully used for
muscle and tendon injuries.12 Additionally, its safety
and potential for reducing pain has previously been
proven in patients with plantar fasciitis.13,14
In its simplest definition, PRP is a blood derivative
with a higher number of platelets than those found in
peripheral blood.15 Currently, PRP can be obtained
through a process of two-phase centrifugation
known as plasmapheresis in which the liquid and
solid components of the anticoagulated blood are
separated. The first phase is carried out at a lower
centrifugation speed (1,200–1,500 rpm), and it
separates the plasma and platelets from the white
and red cells. The second phase is performed at a
higher centrifugation speed (4,000–7,000 rpm) to
increase the concentrations of PRP and platelet-poor
plasma.15 The PRP formulation may vary in cellular
content, which may influence its effects on tissue
healing. Thus, two principal types of PRP are
produced: leukocyte-rich PRP (LR-PRP), which
includes white blood cells, and leukocyte-poor PRP
(LP-PRP), which contains a minimal amount of white
blood cells. The increase in the number of platelets is
also a variable in these samples.12 The white cells, as
well as monocytes and neutrophils, can trigger
localized inflammatory effects. These effects may
suggest that these cells are critical to the repair
process; however, some reports have found that
neutrophils may impede healing.16
Once the PRP is obtained, it can be applied with
an activating agent, such as thrombin, gluconate, or
calcium chloride, to release growth factors rapidly,
or it can be infiltrated directly and thereby produce
a slower release when activated by the collagen in
the area.17,18
In addition to the variations previously described,
other patient factors, such as age and comorbidities,
may also cause variations in the cellular content and
the growth factors in the PRP.19 However, the
optimal amount of platelets and growth factors
required for the healing of tendons or muscles is not
yet known. According to Marx,20 clinical effective-
ness was obtained with a concentration of at least
four times that of the normal platelet concentration.
However, efficacy studies have been performed
with preparations of lower concentrations,21,22
including a study by Giusti et al,23 who proposed
that the most effective platelet concentration for
stimulation of angiogenesis was 1.5 3 106 platelets
per microliter in an in vitro study.
The objective of our study was to compare the
use of intralesional steroids against intralesional
PRP, using pain scales and functional evaluation, in
patients with plantar fasciitis who did not respond
to conservative treatment.
Patients and Methods
A controlled, randomized, blinded clinical assay
was performed (Fig. 1). All of the patients included
in our study were diagnosed with plantar fasciitis in
the outpatient clinic by the same orthopedist
(J.E.R.). All of the patients underwent conventional
radiographs of the foot and magnetic resonance
imaging (MRI) to rule out stress fractures and
associated bone lesions. The inclusion criteria
consisted of skeletally mature patients with heel
pain at the insertion of the plantar fascia (anterior-
medial calcaneal tuberosity), failure of conservative
treatment for 3 months (orthotics and nonsteroidal
anti-inflammatory drugs, without stretching exer-
cise), and no previous infiltrations. The exclusion
criteria consisted of patients with associated
pathologies, such as alterations in the ipsilateral
ankle and knee, osteoarthritis, rheumatoid arthritis,
ankylosing spondylitis, Reiter’s syndrome, neuro-
logical abnormalities, skin infections, or a history of
infection at the application site in the previous 3
months. The ethics committee of our institution
approved this study. All of the included patients
were informed regarding their condition. Likewise,
the purpose of the study was explained to them, and
all agreed to participate by signing an informed
consent form. Patients were assigned to one of the
two groups in a randomized manner by selecting a
sealed envelope. All procedures were applied by the
same researcher (R.L.C.), who was blinded to the
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application through the use of covered syringes;
further assessments were performed by another
investigator (J.E.R.) blinded to the treatment.
Steroid Application
The steroid treatment group received 8 mg of
dexamethasone (Alin Depot; Chinoin, Aguasca-
lientes, Mexico) plus 2 mL of lidocaine as a local
anesthetic. Asepsis of the heel region was per-
formed with antiseptic sanitizer (Avagard; 3M, St.
Paul, Minnesota) for 2 minutes. The drug was
administered afterward by an infiltration in the
anteromedial zone of the calcaneus (zone of
greatest pain).
Preparation and Application of PRP
A 40-mL volume of whole blood was taken from the
basilic or antecubital vein of the upper limb in
sterile tubes and vacuum sealed with 3.8% sodium
citrate as an anticoagulant (BD Vacutainer; Becton,
Dickinson and Company, New Jersey). The samples
were transported to the tissue engineering labora-
tory of the bone and tissue bank where they were
centrifuged for 10 minutes at 1,800 rpm (Heraeus
Megafuge 1.0R; Fisher Scientific, Waltham, Massa-
chusetts) to separate the cellular parts correspond-
ing to the erythrocytes and leukocytes. The upper
plasma layer was removed from each of the tubes
(taking care not to remove the buffy coat) and
collected into a 50-mL sterile conical polypropylene
tube (Falcon; Fisher Scientific, Corning, New York)
for a second centrifugation step for 12 min at 3,400
rpm. The plasma supernatant, or platelet poor
plasma (PPP), was removed, leaving a volume of 3
mL in which the platelets were resuspended. The 3
mL of PRP obtained was transferred to a sterile
glass tube and vacuum sealed without anticoagulant
(BD Vacutainer). An aliquot of the final PRP was
Figure 1. Flow chart of patient selection, randomization, treatment, and evaluation.
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sent to the laboratory to quantify the number of
platelets. Manipulation of the samples was per-
formed in a sterile environment within a class II
biosafety cabinet (Logic 3440801; Labconco, Kansas
City, Missouri). Prior to the administration of PRP
to the patient, activation of the platelets was
induced by adding 0.45 mL of 10% calcium gluconate
and inverting the sample several times to ensure a
homogeneous mixture. Then, the activated PRP was
aspirated with a 5-mL syringe for application to the
patient using the technique described above after
asepsis and the application of 2 mL of lidocaine into
the application site.
Analysis of Whole Blood and PRP Samples
Additionally, for all patients, a blood sample was
obtained in a tube that contained EDTA as an
anticoagulant (BD Vacutainer). An analysis of the
baseline platelet content (in the whole blood) and
the platelet content in each of the PRP samples that
were generated was performed.
Post-Treatment Monitoring and Management of
Patients
All of the patients were given an explanation and
instructions for the exercise program, which con-
sisted of stretching the plantar fascia with the
patient seated while performing an extension of the
toes with his or her hand, and crossing the affected
leg on the opposite thigh. The patients were
instructed to perform 10 repetitions of each
exercise three times a day and to maintain the
exercise for 10 sec during each repetition, according
to DiGiovanni et al.9
All of the patients were evaluated at the beginning
of the study (pretreatment) and at 2, 4, 8, 12, and 16
weeks post-treatment with the Visual Analog Scale
(VAS),24 Foot and Ankle Disability Index (FADI),25
and American Orthopedic Foot and Ankle Society
(AOFAS) scale.26 The VAS assesses the pain level by
assigning a score from 0 to 10, with 0 representing
no pain and 10 representing the worst pain level.
The FADI scale assesses activities such as standing,
walking on flat or uneven surfaces, walking on
inclines, and the length of time of walking without
difficulty. It also includes a section for sports
activities and ankle or foot pain (or both). The
highest score is 136 points, indicating the best
clinical situation, free of pain and limitations, while
the lowest score is 0. The AOFAS scale evaluates
foot pain, function, and alignment. The best score is
100 and indicates wellness, while the lowest score is
0, indicating the worst possible condition of the
patient.
Statistical Analysis
Using a formula to test hypothesis and two media
difference, with a value of za of 1.96 with
significance level of 95 for two tails, and a value
zb of 1.24 with power 90, a sample of 13 participants
for each of the groups was obtained. The results
were reported in contingency tables, frequency
tables, percentages, measures of central tendency
and dispersion. Quantitative variables were ana-
lyzed with a Student t test for independent samples
with a significance level of 95 with their respective
confidence intervals. A P-value of ,0.05 was
considered statistically significant. Statistical anal-
ysis was performed with IBM SPSS version 20
(SPSS, Inc, Armonk, New York).
Results
Demographic data
We included a total of 32 patients divided into two
groups of 16 patients each and excluded two
patients in each group (four total) for not complet-
ing the follow-up. The final number of patients
included was 28, which consisted of 14 patients in
the steroid group (one patient with bilateral
involvement) and 14 patients in the PRP group
(one patient with bilateral involvement), with a total
of 30 treated feet. The right foot was the most
frequently affected foot (63%). The average age of
the patients was 44.8 (range, 24–61) years, and 80%
of the patients were female, while 20% were male.
The patients did not experience any treatment-
related complications in either group. The mean 6
SD of the platelet number in the peripheral blood
and PRP was 270.4 6 71.1 3 10e3/lL and 678.8 6
198.7 3 10e3/lL, respectively, meaning there were
2.5 times more platelets in PRP than in whole blood.
Visual Analog Scale
Before the infiltration, the pain experienced by the
patients included in the steroid-treated group was
more intense and showed statistical significance.
During patient follow-up, an improvement in pain
(decrease in the VAS score) was found in both
groups. The difference was not statistically signif-
icant between the two groups. At the end of the
study, the VAS value in the steroid group was 0.47
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(6 1.3), while the value of the PRP group was 0.33
(6 0.72) (Table 1).
Foot and Ankle Disability Index
During the initial evaluation, no statistically signif-
icant difference between the two groups was found
for the FADI score. During follow-up consultations
(2, 4, 8, 12, and 16 weeks), a progressive increase in
the FADI score was observed in both groups of
patients, reflecting clinical improvement. However,
the difference in improvement between the two
groups during the follow-up consultations was not
statistically significant (Table 2).
American Orthopedic Foot and Ankle Society
Scale
At the beginning of the evaluation, no statistically
significant differences between groups were pre-
sented. Throughout the evaluation period, clinical
improvement in the patients was evident, but no
significant difference between the two study groups
was observed (Table 3).
Discussion
In recent years, the use of PRP has increased in
diverse clinical situations such as biological and
autologous therapeutic alternatives. For the VAS,
we found that at the beginning of the evaluation, the
patients treated with steroids had significantly
greater pain than those in the group that received
PRP (Table 1). However, during all subsequent
evaluations, both groups presented improvement,
and no differences between the groups were found
at the end of the study. For the evaluation of the
FADI and AOFAS functional ankle scales, at the
beginning of the study both groups were similar,
with no differences between them, and all patients
improved throughout the duration of the study
(Tables 2–3). At the end of the study, no significant
differences were observed between the two groups.
One of the key components for the treatment of the
chronic plantar fasciitis involves fascia and gastroc-
soleus complex stretching exercises, as described
above by DiGiovanni et al.9 Therefore, we think that
the intralesional infiltration may be used with
steroids or PRP as an adjuvant for the rapid
alleviation of pain and to initiate the stretching
exercises.
In particular, clinical studies14,27 have reported
the use of PRP as a safe and effective treatment for
plantar fasciitis. In one of these studies, 14
consecutive patients were treated with three injec-
tions of PRP for 12 months. They were assessed
using the modified Roles and Maudsley score as
well as the VAS, and good results were shown in
nine patients (64%). The VAS score decreased
significantly from 7.1 (6 1.1) before treatment to
1.9 (6 1.5) at the final follow-up evaluation (P ,
0.01).14 Double centrifugation PRP was applied to
23 consecutive patients who were the subjects of a
retrospective study, and they were assessed using
the VAS, Medical Outcomes Study Short Form 12
Health Survey, and Foot and Ankle Outcome Score
(FAOS). A mean improvement of the VAS score
from 7 to 4 was found. The FAOS scores for the
pain, symptomatology, and quality of life scales
improved significantly during the follow-up peri-
od.27 In a cohort-type study with two treatment
methods (either steroids or PRP) using a commer-
Table 1. Results of Visual Analog Scale
Time, wk Steroid Group PRP Group P Value
Pretreatment 5.67 6 1.54 4.53 6 1.12 0.02
2 3.33 6 1.67 3.33 6 1.04 0.89
4 2.21 6 1.69 2.42 6 1.45 0.73
8 1.27 6 1.53 1.13 6 1.33 0.79
12 0.53 6 1.06 0.62 6 0.73 0.84
16 0.47 6 1.34 0.33 6 0.72 0.73
Note: Data are provided as mean 6 SD.
Abbreviation: PRP, platelet-rich plasma.
Table 2. Results of Foot Ankle Disability Index (FADI)
Time, wk Steroid Group PRP Group P Value
Pretreatment 66.8 6 12.2 76.2 619.2 0.07
2 100.2 6 20.5 96.6 619.5 0.62
4 116.2 617.8 108.2 6 22.1 0.28
8 123.4 618.6 126.6 6 14.0 0.6
12 132.9 6 7.2 133.9 6 2.7 0.62
16 130.9 615.2 134.8 6 2.7 0.34
Note: Data are provided as mean 6 SD.
Abbreviation: PRP, platelet-rich plasma.
Table 3. Results of AOFAS
Time, wk Steroid Group PRP Group P Value
Pretreatment 67.6 6 10.7 72.3 6 9.1 0.22
2 82.6 6 9.7 80.8 6 6.0 0.54
4 86.8 6 9.8 85.9 6 6.7 0.76
8 91.4 6 10.0 96.1 6 10.1 0.21
12 96.8 6 5.4 94.4 6 5.7 0.25
16 97.2 6 8.4 96.2 6 6.0 0.73
Note: Data are provided as mean 6 SD.
Abbreviation: PRP, platelet-rich plasma.
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cial system and evaluated with the VAS, FADI, and
AOFAS, a significant improvement was found in all
scales after 3 months for patients treated with
PRP.28
A prospective evaluation of the use of double
centrifugation PRP in plantar fasciitis was per-
formed using the VAS pre- and post-application in
addition to an assessment of the plantar fascia
thickness by ultrasound. It was found that the VAS
score decreased from 9.1 prior to the injection to 1.6
following the application. The rate of patient
satisfaction was 88%, and significant changes in
the thickness of the plantar fascia were observed
during the study period. In addition, no complica-
tions were presented during the evaluation.13
Sixty patients with failure of conservative treat-
ment were divided into two groups. The first 30
patients received 40 mg of methylprednisolone, and
the other 30 patients received double centrifugation
PRP. The patients were evaluated with the modified
Roles and Maudsley criteria and the VAS at 3 weeks
and 6 months after injection. No differences in the
VAS were observed between the groups at the end
of the study, but the scores were significantly lower
in both groups compared to the values at the
initiation of the study. Likewise, no differences
were found between the groups when they were
evaluated using the Roles and Maudsley criteria. It
was concluded that both methods are effective for
the treatment of the plantar fascia. In addition, the
use of PRP appears to be advantageous, considering
the possible complications from steroids.29
The weaknesses of our study include the short
follow-up period of the patients, the low number of
patients studied, and the inclusion of more epide-
miological data such as IMC, which has been linked
to an increase in the incidence of this condition.30
The strengths of our study include the use of
validated and standardized scales for this type of
pathology and the absence of complications with
any of the two types of infiltration. Additionally, we
used our double centrifugation technique of PRP
preparation, which has a lower cost than the
commercial method.
We used double centrifugation to obtain the PRP
with the lowest possible amount of white blood
cells; the cells are usually activated with 10%
calcium gluconate. With this procedure, activation
of the PRP is usually achieved between 10 and 15
min after its incorporation, and to date, no
application difficulty has been reported. We can
conclude that the use of PRP is an effective
treatment method for patients with plantar fasciitis
who do not respond to conservative treatment
because PRP demonstrates an efficacy equal to that
of steroids, without presenting, so far, the compli-
cations associated with steroid use that were not
present during the time of this study. On the other
hand, PRP is more expensive than a steroid
infiltration; the process to obtain the PRP requires
more time for the patient and the physician. In
addition, the regenerative properties of PRP on soft
tissues, such as muscles and tendons, could
represent an additional benefit to patients by
reducing inflammation and promoting the regener-
ation of damaged tissue.31 Plantar fasciitis treat-
ment with PRP seems promising; however, more
studies with level 1 evidence are needed to
determine the real beneficial effects of this therapy.
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